Clinical Trials Logo

Open-Angle Glaucoma clinical trials

View clinical trials related to Open-Angle Glaucoma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06061718 Active, not recruiting - Ocular Hypertension Clinical Trials

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Start date: September 11, 2023
Phase: Phase 3
Study type: Interventional

Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.

NCT ID: NCT05456724 Active, not recruiting - Ocular Hypertension Clinical Trials

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start date: August 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension. The proposed trial consists of 3 study parts to be conducted at Nucleus Network Melbourne. This study will enroll up to 34 evaluable healthy volunteers in part 1(SAD) and part 2(MD) and 16 evaluable patients with Open-Angle Glaucoma or Ocular Hypertension in part 3(MD). Note- As of 14Mar2023, enrolment has been completed for Part 1 and Part 2 and recruitment is pending now for Part 3.

NCT ID: NCT05335122 Active, not recruiting - Ocular Hypertension Clinical Trials

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT ID: NCT05160805 Active, not recruiting - Open Angle Glaucoma Clinical Trials

A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle Glaucoma

Start date: May 2, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma. ONL1204 Ophthalmic Solution is a first-in-class inhibitor of fragment apoptosis stimulator (Fas) receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease. Apoptosis of retinal ganglion cells is associated with progressive glaucoma. Nonclinical data on ONL1204 Ophthalmic Solution suggest that ONL1204 Ophthalmic Solution may inhibit the cell death pathways in these cells.

NCT ID: NCT05035394 Active, not recruiting - Cataract Clinical Trials

Swedish Microinvasive Glaucoma Surgery Study (SMIGS)

SMIGS
Start date: September 16, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the efficacy of Cataract Surgery as stand-alone compared to Cataract Surgery in combination with Kahook Dual Blade Glide goniotomy (KDB) or iStent Inject W Trabecular Microbypass Stent (Istent) in eyes with Open-angle glaucoma.

NCT ID: NCT04773106 Active, not recruiting - Glaucoma Clinical Trials

Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery

Start date: February 20, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC system.

NCT ID: NCT04503356 Active, not recruiting - Cataract Clinical Trials

OMNI in Open-angle Glaucoma Treatment

Start date: April 17, 2018
Phase: N/A
Study type: Interventional

This single-center, prospective study will assess safety and effectiveness of 360 degree viscodilation followed by up to 360 degree trabeculotomy used in patients with early or moderate open-angle glaucoma in a real-world setting either as a standalone procedure in pseudophakic patients (or phakic) or combined with phacoemulsification cataract procedures. Medication usage, IOP and secondary surgical procedures necessary for IOP control will be analyzed during the follow-up period.

NCT ID: NCT04060758 Active, not recruiting - Open Angle Glaucoma Clinical Trials

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

Start date: March 11, 2020
Phase: Phase 1
Study type: Interventional

This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.

NCT ID: NCT03904381 Active, not recruiting - Open-angle Glaucoma Clinical Trials

Efficacy and Safety of XEN® Gel Stent and Post-operative Management in Patients With Open Angle Glaucoma

Start date: January 1, 2016
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of postoperative management with 5-fluorouracil injections after XEN Gel Stent implantation.

NCT ID: NCT03850782 Active, not recruiting - Ocular Hypertension Clinical Trials

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Start date: February 28, 2019
Phase: Phase 3
Study type: Interventional

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.